[go: up one dir, main page]

WO2009038107A1 - Préparation pharmaceutique combinée destinée au traitement du diabète de type 2 - Google Patents

Préparation pharmaceutique combinée destinée au traitement du diabète de type 2 Download PDF

Info

Publication number
WO2009038107A1
WO2009038107A1 PCT/JP2008/066809 JP2008066809W WO2009038107A1 WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1 JP 2008066809 W JP2008066809 W JP 2008066809W WO 2009038107 A1 WO2009038107 A1 WO 2009038107A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptable salt
pharmacologically acceptable
diabetes
type
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066809
Other languages
English (en)
Japanese (ja)
Inventor
Mitsutaka Shimasaki
Naoki Kobayashi
Tatsuro Takei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Priority to JP2009533167A priority Critical patent/JPWO2009038107A1/ja
Publication of WO2009038107A1 publication Critical patent/WO2009038107A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique renfermant une combinaison de mitiglinide (qui est une substance utile pour le traitement du diabète de type 2) ou de l'un de ses sels acceptables sur le plan pharmacologique et de pioglitazone ou de l'un de ses sels acceptables sur le plan pharmacologique. L'invention concerne également une préparation pharmaceutique combinée dans laquelle l'effet thérapeutique de la pioglitazone ou de l'un de ses sels acceptables sur le plan pharmacologique sur le diabète de type 2 peut être amplifié chez un patient chez lequel il est impossible de contrôler suffisamment la glycémie par l'administration seule de pioglitazone ou de l'un de ses sels acceptables sur le plan pharmacologique, et où il est impossible d'augmenter de manière synergique les effets secondaires indésirables provoqués par les composants qui y sont renfermés. Ainsi, l'invention concerne spécifiquement une préparation pharmaceutique destinée au traitement du diabète de type 2 qui renferme une combinaison de mitiglinide de formule (Ia) ou l'un de ses sels acceptables sur le plan pharmacologique et de pioglitazone de formule (IIa) ou l'un de ses sels acceptables sur le plan pharmacologique.
PCT/JP2008/066809 2007-09-21 2008-09-18 Préparation pharmaceutique combinée destinée au traitement du diabète de type 2 Ceased WO2009038107A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009533167A JPWO2009038107A1 (ja) 2007-09-21 2008-09-18 ２型糖尿病治療用の組合せ医薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007245437 2007-09-21
JP2007-245437 2007-09-21

Publications (1)

Publication Number Publication Date
WO2009038107A1 true WO2009038107A1 (fr) 2009-03-26

Family

ID=40467917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066809 Ceased WO2009038107A1 (fr) 2007-09-21 2008-09-18 Préparation pharmaceutique combinée destinée au traitement du diabète de type 2

Country Status (2)

Country Link
JP (1) JPWO2009038107A1 (fr)
WO (1) WO2009038107A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (zh) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 一种以盐酸吡格列酮和米格列奈为活性成分的药用组合物及其制备方法、用途
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817347A (zh) * 2006-03-10 2006-08-16 北京阜康仁生物制药科技有限公司 一种以盐酸吡格列酮和米格列奈为活性成分的药用组合物及其制备方法、用途
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EIJI KUDO: "Insulin Chusha kara Mitiglinide eno Kirikae no Kanosei", PHARMA MEDICA, vol. 24, no. 6, 10 June 2006 (2006-06-10), pages 125 - 132 *
MASATOSHI KIKUCHI ET AL.: "Sokkosei·Tanjikan Sayogata Insulin Bunpitsu Sokushin'yaku Mitiglinide to Insulin Teikosei Kaizen'yaku Pioglitazone no Heiyo Ryoho no Yuyosei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-184 *
MASAZUMI FUJIWARA: "SU-yaku kara Mitiglinide eno Kirikae ni yori HbAlC ga Yui ni Teika shita 2-gata Tonyobyo Shorei no Kento", PROGRESS IN MEDICINE, vol. 28, no. 6, 10 June 2008 (2008-06-10), pages 1541 - 1545 *
RYO MORIKAWA ET AL.: "Tandoku o Gappei shita Michiryo 2-gata Tonyobyo no 1-rei", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 50, no. 3, 30 March 2007 (2007-03-30), pages 224 *
SHOICHI HATAKE ET AL.: "Mitiglinide ni yoru To Fukago no Ketto Koka Sayo ni Taisuru Pioglitazone Choki Toyo no Koka -OLETF Rat o Mochiita Kento", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 51, no. 1, 25 April 2008 (2008-04-25), pages S-285 *
SHOICHI HATAKE ET AL.: "Pioglitazone nite Chiryochu no 2-gata Tonyobyo Kanja ni Okeru Mitiglinide Heiyo Koka no Kento -Teiyoryo SU-yaku Heiyo Koka tono Hikaku", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 49, no. 1, 25 April 2006 (2006-04-25), pages S-129 *

Also Published As

Publication number Publication date
JPWO2009038107A1 (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
EA200800198A1 (ru) Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида
WO2006031856A3 (fr) Administration de medicament transdermique biosynchrone
WO2005105213A3 (fr) Derives d'indole et d'azaindole presentant une activite antitumorale
NO2014028I2 (no) Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
WO2007098479A3 (fr) Délivrance localisée d'insuline pour guérison osseuse
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
CL2007002347A1 (es) Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm
WO2009127974A3 (fr) Préparation pharmaceutique pour le traitement de maladies cardiovasculaires
WO2010042471A3 (fr) Dispositifs médicaux pour administration d'agents thérapeutiques à des lumières corporelles
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
WO2007128817A3 (fr) Dérivé insulinique
WO2010015849A3 (fr) Agents thérapeutiques 414
EP2216024A3 (fr) Utilisation de ranolazine pour le traitement de maladies cardiovasculaires
WO2010005980A8 (fr) Tacrolimus pour traitement amélioré de patients transplantés
WO2008149802A1 (fr) Agent anti-fatigue et composition orale comprenant chacun de l'andrographolide en tant que principe actif
TW200604193A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
MX2009011900A (es) Curacion de herida diabetica.
WO2008070010A3 (fr) Rétablissement après une attaque
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009533167

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831697

Country of ref document: EP

Kind code of ref document: A1